Targeting endogenous apo A-I-a new approach for raising HDL

New therapeutic strategies are needed for patients with atherosclerosis. Despite failing to reach its primary end point, a multicenter, phase II, randomized, placebo-controlled trial of RVX-208-an oral, synthetic quinazoline molecule that stimulates expression of endogenous apolipoprotein A-I-has provided somewhat encouraging results. Nevertheless, detailed investigations are still needed if we are ever to realize the full atheroprotective potential of novel HDL-targeted therapies.